Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1621 - Prognostic Merit of Glucose transporter GLUT1 Expression Status in Gastric Cancer (51P)


18 Nov 2017


Poster lunch


Translational Research;  Gastric Cancer


Ji Wang


Annals of Oncology (2017) 28 (suppl_10): x7-x15. 10.1093/annonc/mdx653


J. Wang, X. Ying, L. Wang

Author affiliations

  • Surgical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, 310016 - Hangzhou/CN


Abstract 1621


Glucose transporter 1 (GLUT1), encoded by the SLC2A1 gene, is a vital element in the glucose transport of malignant cells, and abnormally expressed in a great number of human solid cancers. But the association between GLUT1 overexpression and clinical outcome in gastric cancer setting remains to be clarified. Therefore, we carried out this study to evaluate the correlation between GLUT1 expression and clinicopathological and prognostic characteristics in gastric cancer.


The mRNA level of GLUT1 expression in different subtypes of gastric cancer was assessed by using Oncomine database. The correlation between GLUT1 expression levels and clinical survival in gastric cancer patients with diverse clinicopathologic parameters was analyzed by using Kaplan-Meier plotter database. The COSMIC and cBioPortal databases were used for analysis of GLUT1 mutation characteristics and alteration frequency.


Oncomine database showed elevated expression of GLUT1 in different subtypes of gastric cancer. Prognostic analysis revealed that elevated expression status of GLUT1 mRNA was associated with poor overall survival and first progression survival of gastric cancer patients. Low alteration frequency was observed in gastric cancer.


GLUT1 is upregulated in gastric cancer, and its overexpression is related with unfavorable clinical survival, indicating that GLUT1 expression is a significant prognostic biomarker of gastric cancer.

Clinical trial identification

Legal entity responsible for the study

Dr. Ji Wang


National Natural Science Foundation of China (No. 81602471 and No. 81672729) and by grant from Sub project of China National Program on Key Basic Research Project (973 Program) (No. 2014CB744505).


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.